(Q35124682)

6 August 2017

1 reference

title

Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation (English)

1 reference

6 August 2017

0 references

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

1 January 2024

author name string

Rhys B. Vaughan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12739989

1 January 2024

Jaye P. F. Chin-Dusting

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12739989

1 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

http://www.tandfonline.com/doi/pdf/10.1517/14656566.4.5.625

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Expert Opinion on Pharmacotherapy

1 January 2024

published in

1 reference

6 August 2017

volume

4

1 reference

6 August 2017

issue

5

1 reference

6 August 2017

page(s)

625-637

1 reference

The cardiac output at rest in Laennec's cirrhosis

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

GENERAL AND REGIONAL CIRCULATORY ALTERATIONS IN CIRRHOSIS OF THE LIVER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

The effect of age upon liver volume and apparent liver blood flow in healthy man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Natural history of cirrhotic patients with small esophageal varices: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Octreotide for acute esophageal variceal bleeding: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: the European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: a placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Systematic review: terlipressin in acute oesophageal variceal haemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Bacterial infection in the pathogenesis of variceal bleeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Care of patients with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Management of adult patients with ascites caused by cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.5.625

Circulatory changes in chronic liver disease

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Variations in hepatic blood flow in man during health and disease

1 January 2024

5

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension

1 January 2024

9

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Pathogenesis of ascites in cirrhosis

1 January 2024

10

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis

1 January 2024

12

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites

1 January 2024

13

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Pharmacological treatment of portal hypertension: an evidence-based approach

1 January 2024

16

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites

1 January 2024

21

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Short-term effects of propranolol on portal venous pressure

1 January 2024

22

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: the good, the bad, the ugly

1 January 2024

23

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

The effect of the combination of nitroglycerin and propranolol on splanchnic and systemic hemodynamics in a portal hypertensive rat model

1 January 2024

24

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Local arterial vasoconstriction induced by octreotide in patients with cirrhosis

1 January 2024

27

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension

1 January 2024

29

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure

1 January 2024

33

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage

1 January 2024

37

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Haemodynamic effects of enalaprilat on portal hypertension in patients with HBsAg-positive cirrhosis

1 January 2024

40

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis

1 January 2024

42

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Verapamil has no effect on porto-hepatic pressure gradient, hepatic blood flow and elimination function of the liver in patients with liver cirrhosis

1 January 2024

45

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension

1 January 2024

46

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Possible deleterious hemodynamic effect of nifedipine on portal hypertension in patients with cirrhosis

1 January 2024

47

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

1 January 2024

Refractory ascites

50

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites

1 January 2024

51

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Oral misoprostol or intravenous prostaglandin E2 do not improve renal function in patients with cirrhosis and ascites with hyponatremia or renal failure

1 January 2024

56

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Response to Dopamine Hydrochloride in the Hepatorenal Syndrome

1 January 2024

57

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Activated protein C and pulmonary embolism

1 January 2024

59

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Hyperdynamic circulation in cirrhosis: a role for nitric oxide?

1 January 2024

60

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis

1 January 2024

61

1 reference

https://api.crossref.org/works/10.1517/14656566.4.5.625

1 January 2024

Identifiers

1 reference

6 August 2017

1 reference